154 related articles for article (PubMed ID: 24694032)
1. Motor neuron disease: a chemical perspective.
Wood LK; Langford SJ
J Med Chem; 2014 Aug; 57(15):6316-31. PubMed ID: 24694032
[TBL] [Abstract][Full Text] [Related]
2. Is erythropoietin a potential therapy for amyotrophic lateral sclerosis?
Butsch PO; Cudkowicz ME
Exp Neurol; 2007 Jul; 206(1):11-5. PubMed ID: 17498699
[No Abstract] [Full Text] [Related]
3. Complex genetics of amyotrophic lateral sclerosis.
Kunst CB
Am J Hum Genet; 2004 Dec; 75(6):933-47. PubMed ID: 15478096
[No Abstract] [Full Text] [Related]
4. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G
Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555
[TBL] [Abstract][Full Text] [Related]
5. Activation of STAT3 and inhibitory effects of pioglitazone on STAT3 activity in a mouse model of SOD1-mutated amyotrophic lateral sclerosis.
Shibata N; Yamamoto T; Hiroi A; Omi Y; Kato Y; Kobayashi M
Neuropathology; 2010 Aug; 30(4):353-60. PubMed ID: 19925559
[TBL] [Abstract][Full Text] [Related]
6. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.
Petri S; Kiaei M; Kipiani K; Chen J; Calingasan NY; Crow JP; Beal MF
Neurobiol Dis; 2006 Apr; 22(1):40-9. PubMed ID: 16289867
[TBL] [Abstract][Full Text] [Related]
7. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
[TBL] [Abstract][Full Text] [Related]
8. Molecular biology of amyotrophic lateral sclerosis: insights from genetics.
Pasinelli P; Brown RH
Nat Rev Neurosci; 2006 Sep; 7(9):710-23. PubMed ID: 16924260
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis.
Chang-Hong R; Wada M; Koyama S; Kimura H; Arawaka S; Kawanami T; Kurita K; Kadoya T; Aoki M; Itoyama Y; Kato T
Exp Neurol; 2005 Jul; 194(1):203-11. PubMed ID: 15899257
[TBL] [Abstract][Full Text] [Related]
10. Selection and Prioritization of Candidate Drug Targets for Amyotrophic Lateral Sclerosis Through a Meta-Analysis Approach.
Morello G; Spampinato AG; Conforti FL; D'Agata V; Cavallaro S
J Mol Neurosci; 2017 Apr; 61(4):563-580. PubMed ID: 28236105
[TBL] [Abstract][Full Text] [Related]
11. DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis.
Feng X; Peng Y; Liu M; Cui L
Neuropharmacology; 2012 Feb; 62(2):1004-10. PubMed ID: 22056419
[TBL] [Abstract][Full Text] [Related]
12. Impairment of glutamate transport and increased vulnerability to oxidative stress in neuroblastoma SH-SY5Y cells expressing a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis.
Sala G; Beretta S; Ceresa C; Mattavelli L; Zoia C; Tremolizzo L; Ferri A; Carrì MT; Ferrarese C
Neurochem Int; 2005 Feb; 46(3):227-34. PubMed ID: 15670639
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
14. Amyotrophic lateral sclerosis.
Valko K; Ciesla L
Prog Med Chem; 2019; 58():63-117. PubMed ID: 30879475
[TBL] [Abstract][Full Text] [Related]
15. Molecular targets for neuroprotection.
Przedborski S
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():14-8. PubMed ID: 15512862
[TBL] [Abstract][Full Text] [Related]
16. Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.
Lu H; Le WD; Xie YY; Wang XP
Curr Neuropharmacol; 2016; 14(4):314-21. PubMed ID: 26786249
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.
Pandya RS; Zhu H; Li W; Bowser R; Friedlander RM; Wang X
Cell Mol Life Sci; 2013 Dec; 70(24):4729-45. PubMed ID: 23864030
[TBL] [Abstract][Full Text] [Related]
18. Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis.
Rossi S; De Chiara V; Musella A; Cozzolino M; Bernardi G; Maccarrone M; Mercuri NB; Carrì MT; Centonze D
Amyotroph Lateral Scler; 2010; 11(1-2):83-90. PubMed ID: 19452308
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.
Ahn SW; Jeon GS; Kim MJ; Shon JH; Kim JE; Shin JY; Kim SM; Kim SH; Ye IH; Lee KW; Hong YH; Sung JJ
J Neurol Sci; 2014 May; 340(1-2):112-6. PubMed ID: 24680562
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.
Klivenyi P; Ferrante RJ; Matthews RT; Bogdanov MB; Klein AM; Andreassen OA; Mueller G; Wermer M; Kaddurah-Daouk R; Beal MF
Nat Med; 1999 Mar; 5(3):347-50. PubMed ID: 10086395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
